⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNGX News
Tango Therapeutics, Inc.
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
globenewswire.com
ERAS
TNGX
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
globenewswire.com
TNGX
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
globenewswire.com
TNGX
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
TNGX
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
globenewswire.com
TNGX
Form 8-K
sec.gov
TNGX
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
globenewswire.com
NTHI
TNGX
INTS
Form 8-K
sec.gov
TNGX